Oncothyreon Plunges On Drug Fail; Analyst Slashes Target

Loading...
Loading...
Oncothyreon Inc.
ONTY
plunged Tuesday after the company's tecemotide lung cancer treatment failed to show any effects in a trial in Japan. Merck KGaA has exclusive rights to develop and commercialize the drug and informed Oncothyreon it would discontinue the Phase I/II study. Tecemontide is one of four drugs in Oncothyreon's pipeline and Wedbush's Gregory Wade said the lack of tecemotide results in Japan raises doubts about the company's ONT-10 cancer drug. Both tecemotide and ONT-10 stimulate the immune system to recognize and attack cells that express MUC1, a protein found on non-small cell lung, breast, colon, kidney, ovarian, pancreatic, and prostate cancers. ONT-10 is currently being evaluated in Phase 1 clinical trials in patients with solid tumors. Wade maintained an Outperform rating on Oncothyreon but cut his target to $3 from $6 a share. Oncothyreon traded recently at $2.29, down 17.8 percent.
Posted In: Analyst ColorNewsPrice TargetFDAAnalyst Ratings
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...